A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Sara E KochannyFrancis P WordenDouglas R AdkinsDean W LimJulie E BaumanStephanie A WagnerRyan J BrissonTheodore G KarrisonWalter M StadlerEverett E VokesTanguy Y SeiwertPublished in: Cancer (2020)
Combined tivantinib plus cetuximab does not significantly improve the response rate or survival compared with cetuximab alone but does increase toxicity in an unselected HNSCC population. Cetuximab responses appear to be limited to patients who have HPV-negative HNSCC. MET-aberration-focused trials for HNSCC and the use of higher potency, selective MET inhibitors remain of interest.
Keyphrases
- metastatic colorectal cancer
- locally advanced
- wild type
- squamous cell carcinoma
- newly diagnosed
- ejection fraction
- small cell lung cancer
- tyrosine kinase
- clinical trial
- prognostic factors
- rectal cancer
- study protocol
- randomized controlled trial
- high grade
- radiation therapy
- phase iii
- open label
- phase ii
- patient reported
- double blind
- placebo controlled